Publications by authors named "S Mealing"
Background: Three recent randomized controlled trials demonstrated that, in patients with symptomatic paroxysmal atrial fibrillation (PAF), first-line pulmonary vein isolation with cryoballoon catheter ablation reduces atrial arrhythmia recurrence compared to initial antiarrhythmic drug (AAD) therapy. This study aimed to evaluate the cost-effectiveness of first-line cryoablation compared to first-line AADs from a German healthcare payer perspective.
Methods: Individual patient-level data from 703 participants with untreated PAF enrolled into three randomized clinical trials (Cryo-FIRST, STOP AF First and EARLY-AF) were used to derive parameters for the cost-effectiveness model (CEM).
A cost-effectiveness analysis of RefluxStop against relevant therapeutic alternatives for chronic gastroesophageal reflux disease in Sweden.
Expert Rev Pharmacoecon Outcomes Res
October 2024
Article Synopsis
- The standard treatment for GERD is proton pump inhibitors (PPIs), but new options like RefluxStop, a minimally invasive treatment, are emerging.
- A cost-effectiveness analysis using a Markov model showed that RefluxStop is likely more cost-effective than both PPIs and Nissen fundoplication in Sweden, with high probabilities of being cost-effective.
- RefluxStop may provide a better long-term treatment option for GERD patients compared to traditional therapies, as it has shown promising results in terms of cost-effectiveness.
Article Synopsis
- GERD is commonly treated in Italy with proton pump inhibitors or laparoscopic Nissen fundoplication, but a new device called RefluxStop offers an effective alternative.
- A budget impact model was created to evaluate the financial implications of adding RefluxStop as a treatment option over five years, comparing it to standard therapies.
- The introduction of RefluxStop is expected to reduce surgical failures and reoperations while resulting in only a minor increase in the annual budget for GERD treatment in Italy.
Introduction: Three randomised controlled trials (RCTs) have demonstrated that first-line cryoballoon pulmonary vein isolation decreases atrial tachycardia in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drugs (AADs). The aim of this study was to develop a cost-effectiveness model (CEM) for first-line cryoablation compared with first-line AADs for the treatment of PAF. The model used a Danish healthcare perspective.
View Article and Find Full Text PDF